CEBPZ and acute myeloid leukemia: KMT2C mutations were enriched in patients with core-binding factor (CBF) AML [45%, inv(16): n = 3/8, and t(8;21): n = 2/3] but not in patients with a inv(3)/t(3;3) [14.8%, 4/27, Table S2].